We are live on ! Find out more
BDTX icon

Black Diamond Therapeutics

58 hedge funds and large institutions have $37.8M invested in Black Diamond Therapeutics in 2022 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 8 increasing their positions, 25 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

1.41% less ownership

Funds ownership: 59.15% → 57.74% (-1.4%)

16% less funds holding

Funds holding: 69 → 58 (-11)

17% less capital inflows, than outflows

Capital inflows: $3.6M | Capital outflows: $4.32M

35% less call options, than puts

Call options by funds: $50K | Put options by funds: $77K

53% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 19

68% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 25

Holders
58
Holders Change
-11
Holders Change %
-15.94%
% of All Funds
0.93%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
8
Reduced
25
Closed
19
Calls
$50​K
Puts
$77​K
Net Calls
-⁠$27​K
Net Calls Change
-⁠$64​K

BDTX Hedge Fund Activity: Q4 2022 in Review

58 of the 6,245 institutional investors tracked by Wall St. Rank reported a position in Black Diamond Therapeutics (BDTX) for Q4 2022, worth a combined $37.8M — up 4% from $36.4M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of BDTX and 9 opened new positions — a net loss of 10 holders — while 25 trimmed existing stakes and 8 added.

The largest buyer was Citadel Advisors, adding an estimated $1.32M. The largest seller was K2 Principal Fund, cutting an estimated $1.57M.

  • 58 institutional investors held Black Diamond Therapeutics (BDTX) as of Q4 2022, down from 69 in Q3 2022.
  • Funds reported $37.8M of Black Diamond Therapeutics stock for Q4 2022, up 4% quarter-over-quarter.
  • 9 funds opened new Black Diamond Therapeutics positions in Q4 2022 and 19 closed out, a net change of -10 holders.
  • The largest Black Diamond Therapeutics buyer in Q4 2022 was Citadel Advisors, an estimated $1.32M added.
  • The largest Black Diamond Therapeutics seller in Q4 2022 was K2 Principal Fund, an estimated $1.57M sold.

Based on aggregated 13F filings for Q4 2022.